Lisa Campbell
Director of Regulatory Strategy

Lisa Campbell leads the regulatory and medical writing functions at Richmond Pharmacology. She is responsible for guiding regulatory strategy across all clinical studies, overseeing submissions, and supporting regulatory engagements with UK, EU, and international authorities.

She brings over two decades of experience in drug development, clinical medicine, and regulatory science. Lisa previously held senior consultancy positions at NDA Regulatory Science and SSI Strategy, where she advised on global clinical programmes for gene therapies and rare diseases.

During her nine years at the MHRA, Lisa was a Senior Medical Assessor in the Clinical Trials Unit. Her work included developing innovative licensing processes (ILAP), shaping patient and public involvement strategies, and leading assessments for first-in-human and adaptive platform trials.

Lisa trained in Obstetrics and Gynaecology and holds an MD (postgraduate research degree) in Diabetes in Pregnancy. She is widely published in Nature Medicine, BMJ Open, and JAMA, and is an expert in regulatory compliance, trial design, and policy development.

At Richmond Pharmacology, Lisa is focused on delivering innovative, inclusive, and compliant regulatory solutions that accelerate access to new therapies.

Back to experts

Latest news

Five Years Since a World-First CRISPR Breakthrough at Richmond Pharmacology

December 8, 2025
In November 2020, Richmond Pharmacology made medical history when a patient received the first-ever systemically delivered CRISPR therapy, using lipid nanoparticles to edit genes directly inside the human body.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event